7 completed, 2 enrolling by invitation. 6 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 6 |
| Phase 1 | 1 | Completed 1 |
Follow nonacog beta pegol: new trials by email Literature Review of nonacog beta pegol trials Research Report on nonacog beta pegol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B Nonacog beta pegol - Haemophilia B | Phase 3 | Completed | Novo Nordisk A/S | 30 | 2022-05-18 | 2026-01-12 |
| A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN Nonacog beta pegol - Haemophilia B | Enrolling by invitation | Novo Nordisk A/S | 60 | 2019-04-01 | 2026-06-12 | |
| Adverse Event Data Collection From External Registries on Nonacog Beta Pegol Nonacog beta pegol - Haemophilia B | Enrolling by invitation | Novo Nordisk A/S | 10 | 2018-10-01 | 2026-10-08 | |
| Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B nonacog beta pegol - Congenital Bleeding Disorder, Haemophilia B | Phase 3 | Completed | Novo Nordisk A/S | 54 | 2014-07-02 | 2025-12-23 |
| Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B nonacog beta pegol - Congenital Bleeding Disorder, Haemophilia B | Phase 3 | Completed | Novo Nordisk A/S | 13 | 2012-06-07 | 2017-08-23 |
| Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B. nonacog beta pegol - Congenital Bleeding Disorder, Haemophilia B | Phase 3 | Completed | Novo Nordisk A/S | 25 | 2012-05-16 | 2025-12-23 |
| Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773 nonacog beta pegol - Congenital Bleeding Disorder, Haemophilia B | Phase 3 | Completed | Novo Nordisk A/S | 71 | 2012-04-15 | 2018-05-09 |
| Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients nonacog beta pegol - Congenital Bleeding Disorder, Haemophilia B | Phase 3 | Completed | Novo Nordisk A/S | 74 | 2011-04-27 | 2017-07-28 |
| Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B nonacog beta pegol - Congenital Bleeding Disorder, Haemophilia B | Phase 1 | Completed | Novo Nordisk A/S | 18 | 2009-08-01 | 2017-01-20 |
Hemophilia B (9)
Novo Nordisk A/S (9)
United Kingdom (8) · Germany (7) · France (6) · Japan (6) · United States (6) · Italy (5) · Malaysia (5) · Netherlands (5) · Austria (4) · Canada (4) · Greece (4) · Spain (4) · Taiwan (4) · Thailand (4) · Turkey (Türkiye) (4)
PMID 26970716, PMID 27174727, PMID 27352908, PMID 32369845
2009 (1)